Objectives: The aim of this study was to analyse the emergence of carbapenem resistance among hospital strains of Acinetobacter in the Czech Republic.
Introduction
Bacteria of the genus Acinetobacter, with Acinetobacter baumannii in particular, are notorious for their involvement in nosocomial infections and spread among severely ill patients.
1 These organisms are frequently resistant to multiple antimicrobial agents and there are recent reports on strains resistant to virtually all clinically relevant drugs. Extensive genotypic characterization has shown that, within A. baumannii, clusters of highly similar strains occur, which are assumed to represent distinct clonal lineages. Of these, the so-called European (EU) clones I, II and III are widely spread across Europe and include strains that are usually multidrug-resistant (MDR) and associated with outbreaks of hospital infections. 1 -3 Carbapenem resistance in Acinetobacter spp. has emerged as a significant health problem over the last decade, leaving limited options for antimicrobial therapy. 1 This resistance has been attributed to the production of carbapenem-hydrolysing b-lactamases (carbapenemases), although other mechanisms can also be involved, including those that reduce membrane permeability, alter penicillin-binding proteins or expel drugs from the cell.
1 Carbapenemases found in Acinetobacter belong to molecular class D (OXA enzymes) or class B (metalloenzymes of IMP-and VIM-type or SIM-1). The OXA carbapenemases of Acinetobacter are divided into four phylogenetic subgroups: acquired enzymes OXA-23-like, OXA-24-like and OXA-58-like, and OXA-51-like enzymes that are intrinsic to A. baumannii. OXA-51-like enzymes are normally expressed at low levels but can be overexpressed as a consequence of the insertion of an ISAba1 sequence upstream of their genes. 4, 5 Our previous studies showed that resistance of Acinetobacter isolates to carbapenems was rare in the Czech Republic till the early 2000s. 3,6 However, in 2003 and baumannii isolates resistant to these antibiotics were received by the National Institute of Public Health (NIPH) in Prague from several hospitals. This observation gave rise to the current study to analyse the emergence of carbapenem resistance among clinical Acinetobacter isolates at the country level. We investigated prospectively collected Acinetobacter isolates for their species and strain diversity, and for susceptibility to carbapenems and the presence of genes linked to carbapenem resistance. Furthermore, to obtain a comprehensive view of the situation, the susceptibility and presence of genes conferring resistance to other clinically important agents were determined.
Materials and methods

Collection of Acinetobacter isolates
Acinetobacter strains were collected prospectively from 19 diagnostic laboratories in the Czech Republic between January 2005 and April 2006. The laboratories were asked to send clinically relevant isolates of Acinetobacter spp. obtained from patients hospitalized at intensive care units (ICUs) with no more than one isolate per patient and 10 isolates per ICU. Isolates sent to the NIPH were confirmed for the genus identity and presumptively identified to species using a set of biochemical tests 7 and assessed for susceptibility to 12 antimicrobial agents using disc diffusion (see below). Isolates from the same ICU that were indistinguishable from each other according to phenotype were further typed using ApaI macrorestriction analysis by pulsed-field gel electrophoresis (PFGE). From each group of isolates with a common PFGE profile, sharing phenotypic properties and originating from the same ICU, one isolate was selected for further investigation. Thus, a final set of 150 Acinetobacter isolates remained from a total of 265 isolates received by the NIPH. The 150 isolates were from 56 ICUs of 20 hospitals in 15 cities and were recovered from sputum (n ¼ 69), wounds or pus (n¼19), urine (n ¼ 17), blood or intravenous catheters (n ¼ 15) or from other clinical specimens (n ¼ 30).
Genomic fingerprinting and multilocus sequence typing (MLST)
AFLP genomic fingerprinting performed as described 8 was used both to identify strains to species and to classify them at the subspecies (clone, strain) level. DNA macrorestriction analysis by PFGE included digestion of agarose plugs containing genomic DNA with ApaI (New England Biolabs; 30 U per plug) for 2 h at 258C, followed by separation of restriction fragments with a CHEF-DRII device (Bio-Rad) through a 1.2% SeaKem LE agarose gel (Cambrex) in TBE buffer at 148C for 19 h (pulse times 5-20 s at 6 V/cm). The resulting PFGE fingerprints were compared visually: patterns that differed in the position of more than six bands were designated by different capitals, while those differing in the positions of one to six bands were marked with the same letter followed by different numerals (Figure 1) . MLST was based on a sequence analysis of the internal portions of seven housekeeping genes (cpn60, fusA, gltA, pyrG, recA, rplB and rpoB). Details of the MLST scheme including amplification and sequencing primers, allele sequences and STs are available at Institut Pasteur's MLST Web site (www.pasteur.fr/mlst).
Susceptibility testing
Resistance to 12 antimicrobial agents that are primarily effective against susceptible A. baumannii strains was determined by disc diffusion following the CLSI guidelines. 9 The cut-off values for resistance were adjusted according to the distribution of inhibition zone diameters among A. baumannii strains. 3 The agents (content in mg/disc; resistance breakpoint in mm) included gentamicin (10; 14) , netilmicin (30; 14), tobramycin (10; 14) , amikacin (30; 16), ampicillin þ sulbactam (10 þ 10; 14) , piperacillin (100; 17), ceftazidime (30; 17), meropenem (10; 15) , imipenem (10; 15) , ofloxacin (5; 15), sulfamethoxazole þ trimethoprim (23.75 þ 1.25; 15) and doxycycline (30; 15) (Oxoid). MICs were determined by the agar dilution method according to the CLSI guidelines using the CLSI susceptibility and resistance breakpoints. 9 Etest MBL strips (AB Biodisk, Solna, Sweden) as well as a synergy test using imipenem-and EDTA-containing discs 10 were used to screen for metallo-b-lactamase production. 4 To determine the structure of class 1 integron variable regions, PCR mapping and restriction analysis of amplicons obtained by PCR with primers targeting 5 0 and 3 0 conserved integron segments were carried out as previously. 13 The location of ISAba1 in the upstream region of the chromosomal genes encoding OXA-51-like and AmpC-like b-lactamases was determined according to Turton et al. 4 100  95  90  85  80  75  70  65  60  55  50  45  100  95  90  85  80  75  70  65  60  55  50  45 NT  NT  NT  unique  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  unique  NT  NT  NT  unique  unique  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT   NT  NT  NT  unique  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  unique  NT  NT  NT  unique  unique  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT  NT   0  0  0  0  0  0  0   9  9  10  8  9  9  7  8  8  6  9  11  8  9  8  7 A1  A2  A2  A2  A1  A1  A2  A1  A3  A3  A2  A1  A1  A2  A2  A2  A2  A2  A2  A2  A2  A2  A2  A4  A2  A5  A1  A2  A2  A1  A2  A2  A2  A1  A2  A1  A1  A1  A1  A1  A1  A1  A1  A1  A1  A2  A1  A5  A6  A6  A6  A6  A5  A5  A5  A5   A7  A7  A8  A8  A9  A10  A11  A12  A13  A12  unique  B4  B3  B1  B1  B2   A1  A2  A2  A2  A1  A1  A2  A1  A3  A3  A2  A1  A1  A2  A2  A2  A2  A2  A2  A2  A2  A2  A2  A4  A2  A5  A1  A2  A2  A1  A2  A2  A2  A1  A2  A1  A1  A1  A1  A1  A1  A1  A1  A1  A1  A2  A1  A5  A6  A6  A6  A6  A5  A5  A5  A5   A7  A7  A8  A8  A9  A10  A11  A12  A13  A12  unique  B4  B3  B1  B1 genomic sp. 13 TU (n ¼ 8), Acinetobacter calcoaceticus (n ¼ 1), Acinetobacter schindleri (n ¼ 1) or Acinetobacter junii (n ¼ 1). One isolate could not be allocated to any of the known Acinetobacter species. The MICs of imipenem and meropenem for the non-A. baumannii isolates ranged from 0.125 to 0.5 mg/L. All non-A. baumannii isolates were fully susceptible to the 12 antimicrobials tested by disc diffusion, except for four isolates of gen. sp. 3, which were resistant to gentamicin and tobramycin and/or ofloxacin, and for one gen. sp. 13 TU isolate that was resistant to gentamicin and netilmicin. The non-A. baumannii isolates were negative for all resistance genes except for three aminoglycoside resistant isolates of gen. sp. 3, which were PCR-positive for aadB, and for all gen. sp. 13 TU isolates, which were positive for at least one of the genes associated with the AdeABC efflux system.
Gene detection
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Population structure of A. baumannii isolates
The results of cluster analysis of the AFLP fingerprinting of 108 A. baumannii isolates are shown in Figure 1 . Using a cut-off of 80% (which corresponds to the approximate grouping level of strains of the same clone 3, 18 ), the isolates were classified into one major cluster with 66 isolates, two clusters with 5 isolates each, 5 pairs and 22 single isolates. The major cluster and one of the small clusters corresponded to EU clones II and I, respectively, while none of the strains was found to group with strains of EU clone III (data not shown). Most clone II isolates yielded identical or highly similar PFGE patterns ( Figure 2 ) and 45 (68%) of the clone II isolates clustered together according to their AFLP patterns at 90% (Figure 1 ), indicating that they were genetically related at the subclonal level. 18 MLST was performed for seven clone II isolates that differed from each other in PFGE/AFLP patterns or/and in resistance phenotype (Figure 1 ). Six of them had ST2 (2-2-2-2-2-2-2), which seems to be the typical ST of EU clone II (L. Diancourt, V. Passet, A. Nemec, L. Dijkshoorn and S. Brisse, unpublished results), while NIPH 2578 yielded ST47 (2-13-2-2-2-2-2), a single locus variant of ST2.
Resistance of A. baumannii isolates to carbapenems
According to MICs, 85 (79%) A. baumannii isolates were susceptible (MIC 4 mg/L) to both imipenem and meropenem, while 23 (21%) isolates were either intermediate (8 mg/L) or resistant (16 mg/L) to at least one carbapenem (Figure 1) . Out of the 85 susceptible isolates, 40 had MICs 0.5 mg/L for both carbapenems, but 45 showed reduced susceptibility (MICs 1.0 -4.0 mg/L) to at least one carbapenem. All 68 isolates with carbapenem MICs 1 mg/L were also resistant to at least one other antimicrobial agent and belonged to clone II, clone I or three unique AFLP genotypes. None of the isolates was PCR-positive for the genes encoding metallo-b-lactamase IMP-like, VIM-like or SIM-1. In addition, no metallo-b-lactamase activity was detected in any of 16 isolates with imipenem MICs 16 mg/L, using Etest MBL and a double-disc synergy test.
The results of PCR detection of OXA-type carbapenemases are shown in Table 1 . All isolates were positive for bla OXA-51-like , three were positive for bla OXA-58-like and one for bla OXA-24-like . Using the ISAba1 forward primer and the OXA-51-like gene reverse primer, 34 isolates yielded a PCR amplicon of 1.2 kb, which indicates the location of ISAba1 in the upstream region of the OXA-51-like gene of these isolates. 4 The remaining 74 isolates showed no PCR product, although 37 of them were positive for the ISAba1 sequence (Figure 1 ). The isolates with bla OXA-58-like , bla OXA-24-like or/and ISAba1 adjacent to bla OXA-51-like had carbapenem MICs of 2 to .16 mg/L (MIC 50 8 mg/L and MIC 90 16 mg/L), while those without evidence of these genetic structures showed MICs of 0.5 -4 mg/L (MIC 50 0.5 mg/L and MIC 90 2 mg/L) ( Table 1) .
Resistance of A. baumannii isolates to non-carbapenem agents
According to disc diffusion, 33 isolates were fully susceptible to all 12 antimicrobials, while 75 isolates showed resistance to 3 agents (Figure 1 ). The MICs of imipenem and meropenem for the 33 fully susceptible isolates ranged from 0.125 to 0.5 mg/ L, while those of the 75 isolates resistant to 3 agents were between 0.25 and .16 mg/L. Out of these 75 isolates, 5 and 66 belonged to clones I and II, respectively.
There was a good correlation between the presence of the genes associated with resistance to non-carbapenem agents and MIC of these agents. All isolates positive for aphA6 (n ¼ 24), aacC1 (n ¼ 60) and aadB (n ¼ 1) were resistant to or, in a few cases, intermediate to amikacin, gentamicin and tobramycin þ gentamicin, respectively. All 61 tet(B)-positive isolates showed doxycycline MICs 32 mg/L, while the tet(B)-negative isolates had MICs of 8 mg/L. The MICs of ampicillin/sulbactam of 16/8 mg/L were found only in isolates harbouring the bla TEM-1-like gene (n ¼ 53), while all but one isolate with MICs of 8/4 mg/L were bla TEM-1-like -negative. Using the ISAba1 forward primer and the ampC-like gene reverse primer, 68 isolates yielded a PCR product of 750 bp, which indicates the presence of ISAba1 in the promoter region of the ampC-like gene. 17 Ceftazidime MICs against these 68 isolates were 2, NIPH 2895; 3, NIPH 2700; 4, NIPH 2519; 5, NIPH 2981; 6, NIPH 2867; 7, NIPH 2982; 8, NIPH 2990; 9, NIPH 2874; 10, NIPH 2610; 11, NIPH 2578; 12, NIPH 2713; 13, NIPH 2605; 14, NIPH 2666; 15, NIPH 2988; 16, NIPH 2706 . Lane M, molecular size markers (48.5 kb ladder).
32 mg/L, whereas those against 40 isolates without ISAba1 in the promoter region were 8 mg/L (Figure 1 ). Both the adeB and adeS genes that are associated with the AdeABC efflux system were detected in 96 isolates, while seven isolates were negative for both genes and five isolates were positive for only one of the genes. Only the isolates positive for both genes showed increased netilmicin MICs (4 mg/L) (Figure 1) , which may indicate up-regulation of the efflux. 8 The class 1 integrase gene was found in 60 isolates (belonging to either clone I or II) and was unequivocally associated with the aacC1 and aadA1 genes and with PCR products obtained with the primers aimed to amplify variable integron regions. Three different variable regions with the respective sizes of 2.5, 3.0 and 3.5 kb were detected (Figure 1) , and restriction analysis and PCR mapping of these structures revealed that they contained the same genes in the same order [aacC1-(orfX) 1-3 -orfX 0 -aadA1], differing only in the number of orfX copies. 13 
Heterogeneity of resistance phenotypes and genotypes within EU clone II isolates
The susceptibility rates of clone II isolates (n ¼ 66) according to the MIC and the CLSI breakpoints 9 were as follows (% susceptible isolates): imipenem (76), meropenem (70), ceftazidime (5), piperacillin (0), ampicillin þ sulbactam (23), gentamicin (14) , tobramycin (80), amikacin (68), netilmicin (12) , sulfamethoxazole þ trimethoprim (12) , doxycycline (6) , ciprofloxacin (0) and colistin (98). As many as 21 different resistance profiles were identified among these isolates and a similar heterogeneity was revealed at the gene level. The isolates were positive for the tested genes as follows (% PCR-positive isolates): bla TEM-1-like (80), tet(B) (92), tet(A) (5), aacC1 (83), aphA1 (80), aphA6 (30), bla OXA-58-like (3), intI1 (83) and ISAba1 (95). The integron variable regions of 2.5, 3 and 3.5 kb were found in 8, 46 and 1 isolate, respectively. Individual strains carried from 6 to 12 resistance-associated genes in 17 different combinations. Some isolates with the same PFGE patterns and obtained from the same ICU (e.g. NIPH 2893 and NIPH 2873) differed in the combination of resistance genes, whereas other isolates indistinguishable from each other by genotype and phenotype originated from different cities (e.g. NIPH 2601 and NIPH 2991) (Figure 1 ).
Discussion
Of the 150 Acinetobacter isolates in the present study, 146 (97%) were identified as A. baumannii (72%) or other genomic species of the Acinetobacter calcoaceticus -A. baumannii complex (25%). Nearly all strains resistant to multiple antimicrobial agents belonged to A. baumannii, and the vast majority of these MDR isolates were allocated to EU clone I or II. These results are consistent with those of our retrospective study on the A. calcoaceticus -A. baumannii complex isolates collected in Czech hospitals in 1991 -97. 3, 6 However, whereas in the present study, 5 and 66 isolates were allocated to clones I and II, respectively, 39 and 9 isolates from the 1990s were classified into the respective clones. Even though the results of the two studies are not directly comparable as the strain inclusion criteria differed, the data suggest a shift in the recent A. baumannii population towards clone II.
In the present study, 90% of the isolates with decreased susceptibility or resistance to carbapenems (1 mg/L) and 83% of those resistant to one or more non-carbapenem agents belonged to EU clone II. The wide spread of clone II may have resulted from its selective advantage in the antibiotic-rich hospital environment and could further be facilitated by the absence of effective measures to prevent the transmission of MDR microorganisms, a problem commonly encountered in Czech hospitals. Other European studies have also recently reported on the spread of strains of clone II and on the association of carbapenem resistance with these strains. 18, 19 EU clone II thus seems to be particularly successful in its spread in European countries and it is conceivable that the ability of clone II strains to develop carbapenem resistance has substantially contributed to this spread.
Neither metallo-b-lactamase activity nor the genes encoding these enzymes were detected in any of the studied isolates. The genes encoding OXA-23-type carbapenemases were not found either, and those for OXA-24-type or OXA-58-like enzymes were identified only in four carbapenem-resistant isolates. These data indicate that carbapenem resistance in Czech Acinetobacter strains does not result from the presence of acquired carbapenemases. It has recently been shown that the insertion of an ISAba1 sequence upstream of the chromosomal genes encoding OXA-51-type b-lactamases can increase the expression of these genes, which are normally expressed at a low level, and result in carbapenem resistance. 4, 5 In the present study, ISAba1 was located in the promoter region of the bla OXA-51-like gene in half of the clone II isolates and most of these isolates had higher carbapenem MICs when compared with those devoid of ISAba1 in the promoter region. However, similar MICs (2-4 mg/L) were obtained for some isolates regardless of the presence or absence of ISAba1 adjacent to the bla OXA-51-like gene. Carbapenem resistance thus seems to result from the overexpression of the bla OXA-51-like gene, but other mechanisms are probably also involved.
In conclusion, the present study shows that the emergence of Acinetobacter resistance to carbapenems in the Czech Republic was associated with the spread of MDR A. baumannii strains belonging to EU clone II. Carbapenem resistance of these strains is likely to result from up-regulation of the chromosomal OXA-51-like b-lactamase rather than from acquisition of other OXA-or metallo-b-lactamases, but the precise molecular basis of this resistance remains to be resolved. Although the high genomic similarity of most clone II isolates suggests that they represent a recent lineage within the clone, these isolates show a striking variation in the phenotype and genotype of resistance to several clinically important antibiotics. This variation is likely to result from a relatively frequent horizontal acquisition and/or loss of resistance genes as well as from differential expression of intrinsic genes. This striking genetic versatility may endow EU clone II with the ability to develop resistance to nearly all clinically relevant agents.
